Aurora Cannabis Inc. shares are experiencing an uptick in after-hours trading, driven by the company's recent announcement of strong fiscal 2025 second-quarter results. The company reported a record adjusted EBITDA of $10.1 million, marking a significant 210% y/y increase. Additionally, quarterly net revenue rose by 29% y/y to $81.1 million, with a notable 41% growth in global medical marijuana sales. These impressive financial results have likely bolstered investor confidence, contributing to the positive movement in the stock price.
The company's strategic focus on international medical marijuana sales appears to be paying off, as evidenced by the robust growth figures. Aurora Cannabis has also been expanding its product lineup, introducing new ultra-high potency indicas and strains specifically designed for veterans. This product innovation, coupled with the financial performance, has likely played a role in the stock's upward trajectory.
Aurora Cannabis Inc. (ACB) shares rose 1.32% to $4.60 in after-hours trading, following a 2.95% increase to close at $4.54 on November 27, 2024.